LEO Pharma
Industriparken 55
DK-2750 Ballerup
Copenhagen
Tel: 45-4492-3800
Fax: 45-4494-3040
Website: http://www.leo-pharma.com/
Email: leo.group@leo-pharma.com
129 articles with LEO Pharma
-
LEO Pharma Presents New Interim Long-Term Efficacy Data for Adbry™ (tralokinumab-ldrm) in Moderate-to-Severe Atopic Dermatitis at the 2022 RAD Conference
4/11/2022
LEO Pharma A/S, a global leader in medical dermatology, today announced 3-year data that help provide insight into the long-term efficacy profile of Adbry™ (tralokinumab-ldrm) in adult patients with moderate-to-severe atopic dermatitis (AD).
-
Sequence Bio announces Discovery Collaboration Agreement with LEO Pharma
4/7/2022
Sequence Bio announced today that it has entered into a collaboration agreement with Danish dermatology specialists LEO Pharma, for use of Sequence Bio's proprietary discovery platform to identify novel dermatologic drug targets.
-
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
-
LEO Pharma Presents New Interim Long-Term Safety and Efficacy Data for Adbry™ (tralokinumab-ldrm) in Moderate-to-Severe Atopic Dermatitis at the 2022 AAD Annual Meeting
3/25/2022
LEO Pharma A/S today announced up to 3.5-year data that further support the long-term safety and efficacy profile of Adbry™ (tralokinumab-ldrm) in adult patients with moderate-to-severe atopic dermatitis (AD). Interim results were shared as a poster presentation at the American Academy of Dermatology (AAD) 2022 Annual Meeting.
-
LEO Pharma A/S Appoints Brian Hilberdink New President of LEO Pharma Inc. United States
2/17/2022
LEO Pharma A/S today announced it has appointed Brian Hilberdink new Executive Vice President and President of LEO Pharma Inc. in the United States, effective March 14, 2022.
-
This week, two biotechnology firms announced new leadership, David Nassif, J.D., and Christophe Bourdon.
-
LEO Pharma announces FDA approval of Adbry™ (tralokinumab-ldrm) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis
12/28/2021
LEO Pharma Inc. announced that the U.S. Food and Drug Administration has approved Adbry™ for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
-
The decision to allow the release of Adbry follows positive results from the Phase III ECZTRA trials, which covered almost 2,000 patients living with moderate to severe atopic dermatitis.
-
Genoskin’s solution is to develop the technologies to replace animals and humans in clinical studies with virtual models, steadily pushing living creatures further and further from testing.
-
Tralokinumab Achieves Primary and Secondary Endpoints in Phase 3 Trial of Adolescents With Moderate-to-Severe Atopic Dermatitis
10/22/2021
LEO Pharma A/S today announced 16-week results of a 52-week monotherapy trial showing tralokinumab significantly improved primary and secondary measurements of efficacy among adolescents (aged 12 to 17) with moderate-to-severe atopic dermatitis.
-
Skin health logged major wins this week after two companies announced positive clinical trial results.
-
The Product Monograph for Protopic® has been updated
10/4/2021
LEO Pharma Inc. announced that Health Canada has approved an update to the Product Monograph of Protopic®, removing the Serious Warnings and Precautions box, also referred to as a boxed warning, regarding a potential association with the use of topical calcineurin inhibitors and malignancy.
-
It was a busy week for clinical trial news. Here’s a look.
-
LEO Pharma presents interim data from Phase 3 tralokinumab long-term extension trial in moderate-to-severe atopic dermatitis at EADV 30th Congress
9/30/2021
LEO Pharma A/S announced results showing adult patients with moderate-to-severe atopic dermatitis maintained improvements in signs and symptoms, itch severity and sleep interference following two years of continuous treatment with tralokinumab.1 Interim findings from the Phase 3 ECZTEND trial were shared as an oral presentation during the European Academy of Dermatology and Venereology Congress 2021.
-
LEO Pharma and Veeva Systems Partner for Patient-centric Digital Trials
9/29/2021
LEO Pharma , a global leader in medical dermatology, and Veeva Systems (NYSE: VEEV) today announced a strategic technology partnership to enable scalable digital trials that are patient-centric and paperless.
-
The U.S. FDA has released a Complete Response Letter (CRL) following its review of LEO Pharma’s tralokinumab. Further data on a device component is the issue brought to light by the recently completed Biologics License Application (BLA) review.
-
LEO Pharma to Highlight New Data in Medical Dermatology at EADV Virtual 2020
10/27/2020
LEO Pharma Inc. today announced that data from across its dermatology portfolio of approved and investigational medicines will be presented at the 29th Congress of the European Academy of Dermatology and Venereology (EADV), Vienna, Oct. 29-31, 2020. EADV’s 29th Congress will be fully virtual.
-
LEO Pharma Announces British Journal of Dermatology Publication of Three Pivotal Ph 3 Trials of Tralokinumab
10/16/2020
LEO Pharma Inc., a global leader in medical dermatology, today announced that the British Journal of Dermatology has published primary data from the pivotal ECZTRA 1, 2 and ECZTRA 3 Phase 3 trials of tralokinumab in adult patients with moderate-to-severe atopic dermatitis (AD).
-
UNION therapeutics announces acquisition of PDE4i compound class from LEO Pharma with oral lead candidate (orismilast) in Phase 2
7/21/2020
Candidates in the LEO PDE4 inhibitor compound series have demonstrated potential to become `best-in-class' based on Phase 2 studies in psoriasis (oral) and atopic dermatitis (topical)
-
Kubota Vision Announces Signing of Open Innovation Agreement with LEO Pharma A/S to Screen Novel VAP-1 Inhibitor Compounds for Inflammatory Skin Diseases
4/16/2020
Kubota Vision Inc., formerly known as Acucela Inc., a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., announced the signing of an Open Innovation Agreement with LEO Pharma A/S to screen novel Vascular Adhesion Protein-1 inhibitor compounds discovered by Kubota Vision.